display
Tübingen (dpa) - The Tübingen bio-pharmaceutical company Curevac has raised 450 million US dollars in a capital increase.
Five million shares were issued at an issue price of $ 90 each, as the company announced on Tuesday.
CureVac has been listed on the New York Nasdaq since August 2020.
The pharmaceutical giant Bayer and Curevac announced on Monday that they had expanded a cooperation that had already been concluded at the beginning of January.
Bayer plans to produce 160 million cans in 2022, and more in the second year.
The start is planned for the end of 2021.
Curevac is currently developing the vaccine.
Like the vaccines from Biontech and Moderna, it is based on so-called "messenger RNA" (messenger RNA).
Through the cooperation with Bayer, Curevac hopes to be able to use its corona vaccine this summer.
In addition to Bayer, there are other cooperation partners such as Wacker Chemie from Munich and Rentschler Biopharma from Laupheim (Biberach district).
display
© dpa-infocom, dpa: 210202-99-270280 / 2
Announcement of the capital increase on January 28, 2021
Notification of the Vollzu dated 2.2.2021